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The term photosensitivity broadly refers to the skin’s sensitivity
to sunlight. It often presents as a photodistributed rash, affecting
the forehead, cheeks, nape of the neck, upper chest, upper back,
and extensor arms, with sparing of the nasolabial fold, upper eyelids, submentum, and postauricular area.1 Although this definition
and clinical presentation are generally accepted, there is a range of
photodermatoses with different pathophysiologies. To better understand and treat these photodermatoses, it is important to classify and define them accordingly. In this article, we review the
mechanisms and etiologies of selected, more commonly encountered light-mediated skin conditions: phototoxicity, photoallergy,
and immune-mediated photodermatoses.

PHOTOTOXICITY
Phototoxicity occurs when exposure to a phototoxic agent and
light cause direct cellular injury and necrosis to the skin. When
ultraviolet radiation (UVR) comes in contact with a specific
phototoxic agent (classically a drug or its metabolites) cytotoxic
compounds such as reactive oxygen species and other inflammatory mediators are generated, damaging cellular lipids, proteins,
and DNA with associated cell death.2 UV A (UVA) radiation is
most often responsible for triggering phototoxic reactions, but
UV B (UVB) radiation and visible light can also cause phototoxicity.2 These reactions typically present as an exaggerated
sunburn-like reaction in UVR-exposed areas.2 Biopsy of affected
areas shows keratinocyte necrosis, edema, and lymphocytic and
neutrophilic infiltrates.2
Drug-induced phototoxicity does not require prior sensitization
to the offending drug. Systemic medications are more commonly
implicated than topical medications are. Classically, the resultant
rash develops within minutes to hours after exposure to light.
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There can be a dose-response gradient between the amount of
drug consumed and severity of the skin reaction.3 Because anyone
can theoretically be affected, its overall incidence is high when
compared with that of true photoallergic reactions.2,3 However,
the diagnosis of a drug-induced phototoxic dermatitis can be challenging and is often reliant on previously reported data on the suspected agent. In a systematic review looking at 240 eligible
studies of drug-induced phototoxicity from oral medications,
Kim et al found that most drugs implicated as a phototoxic agent
were supported by very-low-quality or low-quality evidence, using the Grading of Recommendations, Assessment, Development, and Evaluation approach.3 In this systematic review, oral
medications with stronger evidence include vemurafenib, nonsteroidal anti-inflammatory drugs, and antibiotics (specifically, fluoroquinolones and tetracycline). The most frequently reported
drugs were vemurafenib, voriconazole, doxycycline, hydrochlorothiazide, amiodarone, and chlorpromazine.3 It is important to
recognize patients who are taking phototoxic drugs before administering phototherapy and obtaining a minimal erythemal dose
(MED) when appropriate. In a study of 1125 patients treated
with oral methoxsalen photochemotherapy (psoralen plus ultraviolet A therapy) for psoriasis, Stern et al found that patients taking
phototoxic agents did not develop increased delayed erythema
during the initial clearing phase of treatment.4 After the clearing
phase, however, those who were older than 45 years and taking a
phototoxic drug had a 2.3 times greater chance of stopping phototherapy than did those not taking a phototoxic drug.4 Similarly, in
a study looking at 880 patients getting narrowband UVB therapy,
Harrop et al found that patients taking phototoxic medications
were more likely to have grade 2 and grade 3 erythema episodes
than were patients not taking such medications.5
Phototoxic reactions can also occur in response to phototoxic
agents that are applied to the skin. Therapeutically, topical
psoralen and aminolevulinic acid are used in dermatology for
their phototoxic properties in conjunction with exposure to UVA
radiation and visible light, respectively, to treat various dermatologic conditions. Plants containing furocoumarins (botanical
phototoxic agents) can induce a phototoxicity after topical
exposure, which is known as phytophotodermatitis. Plants from
the families Umbelliferae, Rutaceae, and Moraceae, such as
celery, bergamot orange and lime, and mulberry, respectively, are
known to have high levels of furocoumarins and are known to
cause phytophotodermatitis in combination with UVR therapy.
A thorough history taking can often be invaluable in diagnosing
this condition.1
In patients suspected of phototoxic reactions, phototesting is
the criterion standard for diagnosis, but it is not widely available.
Phototesting is performed by determining the MED by exposing
photoprotected areas to increasing increments of UVA and UVB
radiation. Reading is performed immediately (for diagnosis of
solar urticaria) and at 24 hours. Low MED values at 24 hours
would indicate drug-induced phototoxicity.1 If phototesting is not
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FIG 1. Schematic depicting mechanism of photoallergy.

TABLE I. List of common photoallergens by class of medications
Class of medication

Systemic agents

Topical agents

Antibiotics

Dapsone, doxycycline, isoniazid, quinolones, tetracycline

Bithionol, chlorhexidine, dibromosalicylanilide, fenticlor,
hexachlorophene, tetrachlorosalicylanilide

Other anti-infective
agents
Psychotropic drugs

Efavirenz, griseofulvin

Acyclovir, bromochlorosalicylanilide, buclosamide,
thiobischlorophenol

Cardiovascular drugs

Chemotherapeutic
agents
NSAIDs

Amitriptyline, chlordiazepoxide, chlorpromazine,
clomipramine, citalopram, flupentixol, fluphenazine,
fluvoxamine, perazine, paroxetine, perphenazine,
sertraline, thioridazine, trifluoperazine
Amiodarone, captopril, diltiazem, enalapril, fenofibrate,
hydrochlorothiazide, methyldopa, ramipril, quinidine,
simvastatin, valsartan
Tegafur, vandetanib
Aceclofenac, benzydamine, celecoxib, diclofenac,
ketoprofen, piroxicam, suprofen, tiaprofenic acid

UV filters
Others

Benzydamine, diclofenac, ketoprofen, piroxicam
Avobenzone, cinnamates, dibenzoylmethanes, mexenone, ecamsule,
octocrylene, oxybenzone, PABA, salicylates, sulisobenzone

Quinine, sulfonamides, sulfonylureas

Chlorpromazine, dibucaine, fenofibrate, hydrocortisone,
sulfonamides

Data from Lim et al,1 Bylaite et al,7 Greenspoon et al,8 and Onoue et al.9
NSAID, Nonsteroidal anti-inflammatory drug; PABA, p-aminobenzoic acid.

available, challenge-rechallenge testing, during which resolution
of the cutaneous reaction occurs with withdrawal of the suspected
agent and recurrence occurs with its reintroduction, can be confirmatory of a phototoxic reaction.

PHOTOALLERGY
Photosensitizers is a term that covers phototoxic agents and
photoallergens. Phototoxic agents (eg, psoralens) induce direct
tissue damage in the presence of the action spectrum. In
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TABLE II. Immune-mediated photodermatoses and additional features
Immunemediated
photodermatosis

Population affected

Time of onset after
sun exposure

PMLE/JSE

Children and adults;
female predominance

Minutes to hours,
rarely days after
exposure

Hydroa
vacciniforme

Children; male
predominance

Hours to a few days
after exposure

Actinic prurigo

Children; with female
predominance,
primarily affecting
indigenous tribes of
North, Central, and
South America

Persistent and
chronic;
exacerbated in
the summer
months

Solar urticaria

Adults; rarely in
children

Within minutes of
sun exposure

CAD

Adults aged >50 years;
male predominance;
in United States, it is
more common in
FST types IV and V

Persistent and
chronic with
flaring in
summertime

Clinical features

Histologic features

The most common
photodermatosis, most
commonly presenting in spring
and summer, with
immunologic tolerance
(hardening) as the season
progresses; presents as papules,
plaques, and vesicles in sunexposed skin; JSE is a clinical
variant found in children that
predominantly affects the ears
Summer months; discrete
erythematous macules that
evolve into vesicles and
umbilicated papules with crusts
and pits and heals with
varioliform scarring
Associated with
HLADRB1*0407; presents
with flat, shiny, and polygonal
papules coalescing into
lichenified plaques on sunexposed face and extremities;
associated with cheilitis,
conjunctivitis, and
photophobia; leonine facies
can develop in chronic and
severe disease
Presents as urticarial papules and
plaques that resolve <24 hours
after withdrawal of sun
exposure; can be associated
with angioedema and
constitutional symptoms such
as headache, dizziness, nausea,
and wheezing
Can be associated with contact
allergy or photocontact allergy
to Compositae oleoresins
(airborne plant allergen);
presents as confluent
eczematous and lichenified
plaques on sun-exposed scalp,
face, neck, trunk, and
extremities, often with sparing
of skin creases and sunprotected skin; consider HIV
infection in younger
individuals with CAD

Phototesting

Proposed pathophysiology

Spongiosis, focal edema, with
occasional vesiculation and
prominent lymphocytic
infiltrate with occasional
eosinophils and neutrophils

Tends to demonstrate
normal MED

Reduced level of
photoimmunosuppression
leading to enhanced
immune response to
neoantigens in the skin
caused by sun exposure,
resulting in a delayed type
IV hypersensitivity
reaction

Intraepidermal multilocular
vesicles with hemorrhage and
inflammation; epidermal
and dermal necrosis and
mononuclear cell infiltrate can
be seen in late lesions
Nonspecific; hyperkeratosis,
spongiosis, with significant
perivascular lymphocytic
infiltrate and papillary dermal
edema

Often demonstrates
decreased MED for
UVA

Pathophysiology is unknown
but thought to be
associated EBV infection

May be positive for
UVA or normal

Autoantigens exposed by UV
radiation resulting in
delayed type IV
hypersensitivity reaction
in genetically susceptible
individuals

Similar to urticaria, with mild
dermal edema with sparse
perivascular infiltrate with
neutrophils, lymphocytes, and
eosinophils

Positive for immediate
urticarial plaques
with UVB, UVA, and
visible light

IgE-mediated, immediate
type I hypersensitivity
reaction to endogenous
photoallergen

Nonspecific spongiosis and
acanthosis of the epidermis,
with lymphohistiocytic
infiltrate; papillary dermal
fibrosis in chronic cases

Can demonstrate
decreased MED for
UVA, UVB, and/or
visible light

Similar to PMLE, with
reduced level of
photoimmunosuppression
leading to enhanced
immune response to
neoantigens in the skin
caused by sun exposure,
resulting in a delayed type
IV hypersensitivity
reaction

Data from Lim et al1 and Bylaite et al.7
CAD, Chronic actinic dermatitis; FST, Fitzpatrick skin type.

contrast, photoallergens undergo activation by UV therapy,
typically UVA therapy, and covalently bond with endogenous
proteins in a process called haptenization.2 Once haptenization
occurs, these photoallergens are subsequently processed by
Langerhans cells in the epidermis, resulting in increased production of IL-1b and increased production of TNF-a by
epidermal keratinocytes, promoting the migration of Langerhans cells expressing MHC II–photoallergen complexes to the
lymph nodes. In the lymph nodes, these Langerhans cells present their MHC II–photoallergen complexes to naive T cells to
produce mature photoallergen-specific memory T cells.2 This
results in the development of a cell-mediated response
following subsequent exposures (Fig 1). The mechanism of photoallergy parallels that of allergic contact dermatitis, but with
the requirement of light-induced activation. Therefore, photoallergy classically presents as an eczematous eruption on photoexposed skin. Nonetheless, phototoxicity and photoallergy can

often be clinically difficult to distinguish. Biopsy of the
involved skin demonstrates acute spongiotic dermatitis with superficial perivascular lymphocytic inflammation.2
Given the more selective conditions required to produce a
photoallergic reaction, photoallergy is far less common than
phototoxicity. Because sensitization is necessary, photoallergy does not occur after the first exposure. Subsequent
exposures typically induce a delayed response occurring from
hours to several days after exposure.2 Both topical and systemic agents have been implicated in photoallergy. Topically,
nonsteroidal anti-inflammatory drugs and sunscreens have
been the main causes of photoallergic contact dermatitis
since the 1980s.6 The most common photoallergen in sunscreens is oxybenzone. Systemically, the implicated classes
of medications include antibiotics, cardiovascular drugs,
nonsteroidal anti-inflammatory drugs, and psychotropic drugs
(Table I).1,7-9
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Photopatch testing can identify patient-specific photoallergens.
On day 1, determination of the MED to UVB and UVA therapy is
performed, and the suspected photoallergens are placed in
duplicate onto a patient’s back, after which the sites are covered.
On day 2, reading of the MEDs is done. On the same day, 1 set of
photoallergens will then be exposed to UVA radiation. The UVA
radiation dose used is 10 J/cm2, or for those with decreased a
MED to UVA radiation, 50% of the MED for UVA. The sites
will then be covered again, and reading is done on day 3.1,2,6
A positive read on nonirradiated skin suggests an allergic contact
dermatitis in response to that specific allergen, whereas a positive
read on irradiated skin together with a negative read on nonirradiated skin suggests a photoallergic process.2 Although photopatch
testing can be an invaluable tool in identifying photoallergens, it
is not widely available and the testing process is not standardized.
In a survey of American Contact Dermatitis Society members,
less than 50% of the 112 respondents performed photopatch
testing.6 Additionally, among those who did perform photopatch
testing, duration of patch placement, determination of the MED
before photopatch testing, use of UV light (dose and UVA vs
UVB), and the specific photopatch series used varied greatly, suggesting a further need for improved guidelines for phototesting.6

IMMUNE-MEDIATED PHOTODERMATOSES
Immune-mediated photodermatoses are a group of disorders
caused by altered skin immunity when the skin is exposed to
sunlight. Clinically, they have diverse presentations but tend to
worsen in the spring or summer owing to the increased intensity of
sunlight.1,7 Immune-mediated photodermatoses include polymorphous light eruption (PMLE)/juvenile spring eruption, hydroa vacciniforme, actinic prurigo, solar urticaria, and chronic
actinic dermatitis.
These disorders can affect patients of all ages and all skin types,
although age and racial differences can be appreciated in the
distribution of photodermatoses.10 PMLE is the most common
photodermatosis in both adults and children.10 In a large retrospective chart review study involving 4 academic institutes, Hamel et al found that PMLE was more common in Black
patients, whereas photoallergic contact dermatitis, phototoxic
drug eruptions, phytophotodermatitis, porphyrias, and solar urticaria were more commonly found in White patients.10
To differentiate between various immune-mediated photodermatoses, a thorough patient history, including the age of
onset, seasonality, onset and duration of episodes, and family
history of similar findings, along with a detailed skin examination
and when appropriate, skin biopsies and additional testing, can be
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invaluable in determining the diagnosis.1,7 Phototesting by irradiating uninvolved skin with increasing doses of UVA, UVB, and/or
visible monochromatic or broad-spectrum radiation can help diagnose chronic actinic dermatitis and solar urticaria, but the results can often be normal in PMLE.1 Additional information
regarding the features of each individual immune-mediated photodermatosis can be found in Table II.

CONCLUSION
Phototoxicity, photoallergy, and immune-mediated photodermatoses can all cause photosensitivity. There is clinical overlap
between these conditions; therefore, a thorough patient history,
family history, and medication list should be obtained, and a
physical examination looking closely at morphology and distribution of skin findings should be performed.1 Phototesting, photopatch testing, and biopsy can also be helpful. Photoprotection
with a broad-spectrum, tinted UV filter with a high sun protection
factor is the mainstay of treatment. In cases of phototoxicity and
photoallergy, removal of exposure to the precipitating agent
should be done if possible. It is important to recognize these disorders, refer the patient for pertinent diagnostic testing, and treat
the disorder appropriately for better patient outcomes.
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